Last edition
News about "phase 3 clinical trial schizophrenia"
Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study
Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.
Phase 3 Clinical Trial Schizophrenia | 02/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members